JPRN-UMIN000028517已完成未知
A feasibility study of EdoXaban for the Cancer-Associated asymptomatic Venous thromboEmbolism in Japanese gastrointestinal cancer patients receiving chemotherapy. (ExCAVE study) - ExCAVE study
HGCSG(Hokkaido Gastrointestinal Cancer Study Group)0 个研究点目标入组 100 人开始时间: 2017年8月22日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 90years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1) Symptomatic VTE or PE at the time of diagnosed. 2) Patients who had received thrombectomy,IVC filter catheterization, and any other anticoagulant therapy. 3) In investigator's decision that the case need to be treated as acute VTE. 4) No prior screening tests for the presence of venous thromboembolic disease was performed, such as computer tomography and/or venous ultrasonography. 5) Planned treatment with a vitamin K antagonist. 6) Patients who had received treatment for more than 72 hours with therapeutic doses of heparin, low-molecular-weight heparin, more than twice dose of a vitamin K antagonist. 7) Active bleeding 8) Having several high risk factor of VTE within 3 months. 9) Known protein C or S deficiency, antithrombin deficiency, hyperhomocysteinemia, and anti-phospholipid antibody syndrome. 10) Severe hypertension which have poorly controlled despite the medication. 11) continued to receive treatment with NSAIDs except an aspirin at a dose of more than four days a week. 12) continued to receive treatment with aspirin at a dose of more than 100mg daily or dual antiplatelet therapy. 13) contined to receive treatment with dronedarone. 14) Renal dysfunction (CCR under 30mL/min) 15) Accumulation of pleural, ascitic, or pericardial fluid requiring drainage 16) Any other active illness such as severe cardiac disease (e.g. myocardial infarction, angina pectoris, arrhythmia, or cardiac failure). Any of the following events within the 24 weeks prior to enrollment. 17) Serious hypersensitivity to any drug. 18) Current severe liver disease. 19) Active infection and/or inflammatory diseases. 20) Severe cardiac failure (over NYHA II) 21) Ineligible for participating in this study according to the investigator.
研究者
相似试验
已完成
不适用
ExCAVE studyGastrointestinal cancer: colorectal cancer, non-colorectal cancerJPRN-jRCTs011180030Komatsu Yoshito53
进行中（未招募）
1 期
EDOXABAN TREATMENT VERSUS VKA IN PATIENTS WITH AF UNDERGOING PCI.MedDRA version: 20.0Level: PTClassification code 10003658Term: Atrial fibrillationSystem Organ Class: 10007541 - Cardiac disordersEUCTR2016-002683-14-NLDaiichi Sankyo Europe GmbH1,506
进行中（未招募）
1 期
EDOXABAN TREATMENT VERSUS VKA IN PATIENTS WITH AF UNDERGOING PCI.EUCTR2016-002683-14-ATDaiichi Sankyo Europe GmbH1,500
进行中（未招募）
1 期
EDOXABAN TREATMENT VERSUS VKA IN PATIENTS WITH AF UNDERGOING PCI.EUCTR2016-002683-14-LTDaiichi Sankyo Europe GmbH1,500
进行中（未招募）
1 期
EDOXABAN TREATMENT VERSUS VKA IN PATIENTS WITH AF UNDERGOING PCI.Subjects with atrial fibrillation (AF) following successful PCI with stent placement.MedDRA version: 20.0 Level: PT Classification code 10003658 Term: Atrial fibrillation System Organ Class: 10007541 - Cardiac disordersEUCTR2016-002683-14-IEDaiichi Sankyo Europe GmbH1,500